About
Andy Crew, Ph.D. is a medicinal chemist and drug-discovery executive best known for early leadership at Arvinas, where he was the first employee and later Chief Technology Officer. He also served as CTO of Siduma Therapeutics and, as of October 23, 2024, joined General Proximity's Scientific Advisory Board. His career also includes senior drug-discovery roles at OSI Pharmaceuticals/Astellas, Tularik, and BASF/Knoll.
Areas of interest
biotechdrug discoverymedicinal chemistrytargeted protein degradationPROTACsinduced proximityoncologysmall moleculescardiovascular disease